EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains

Danny Zakria, Milaan Shah, Angela Rosenberg, Joshua Burshtein, Lauren DeBusk, David A Altman, April W Armstrong, Alice B Gottlieb, George Han, Saakshi Khattri, Sheila Shaigany, Jeffrey M Weinberg und 1 weitere

Dermatology Online Journal · 09.05.2026 · 32 (2)

DOI: 10.25251/zsav4a48 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Danny Zakria und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, Interleukin-17, Interleukin-23. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

disease affecting peripheral joints, entheses, skin, and nails. Despite multiple available biologic therapies, unmet needs persist, particularly in patients with multisystem involvement or prior biologic failure. Interleukin-17 (IL-17) and interleukin-23 (IL-23) pathway inhibitors are widely used in PsA; however, important differences exist in their clinical efficacy across disease domains.

Methods

A comprehensive literature review was conducted using PubMed, Scopus, and Google Scholar to identify randomized controlled trials, long-term extension studies, mechanistic studies, and meta-analyses evaluating IL-17 and IL-23 inhibitors in PsA and related spondyloarthritides. A multidisciplinary panel of expert dermatologists and rheumatologists convened for a structured roundtable discussion. A modified Delphi process was used to develop and approve consensus statements. Strength of Recommendation Taxonomy (SORT) criteria were applied to each statement.

Results

Eight consensus statements were unanimously adopted. These statements address radiographic progression, axial disease, mechanistic considerations of IL-17A and IL-17F inhibition, comparative efficacy of bimekizumab, treatment sequencing, and safety considerations including candidiasis, hepatic effects, and psychiatric outcomes.

Conclusion

Based on the totality of available evidence, IL-17 inhibitors play an important role in the management of PsA across multiple disease domains. Differences between IL-17 and IL-23 pathway inhibition have important implications for treatment selection, particularly in patients with axial disease, significant skin involvement, or prior biologic failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, PsoriaticInterleukin-17Interleukin-23HumansAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

IL-17 inhibitorsIL-23 inhibitorsPsAbiologicspsoriasispsoriatic arthritis

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsbimekizumabInterleukin-17Interleukin-23secukinumab

Autor:innen und Institutionen

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Dermatology, Medical University of South Carolina, Charleston, SC, USA.
  • Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.
  • Department of Dermatology, University of Illinois-Chicago, Chicago, IL, USA.
  • Midwest Center for Dermatology and Cosmetic Surgery, Warren, MI, USA.
  • Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Zitieren

APA

Zakria, D., Shah, M., Rosenberg, A., Burshtein, J., DeBusk, L., Altman, D. A., Armstrong, A. W., Gottlieb, A. B., Han, G., Khattri, S., Shaigany, S., Weinberg, J. M., & Lebwohl, M. (2026). The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains. Dermatology Online Journal, 32(2). https://doi.org/10.25251/zsav4a48

Vancouver

Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, et al. The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains. Dermatology Online Journal. 2026;32(2). doi:10.25251/zsav4a48

BibTeX
@article{Zakria2026,
  author = {Zakria, Danny and Shah, Milaan and Rosenberg, Angela and Burshtein, Joshua and DeBusk, Lauren and Altman, David A and Armstrong, April W and Gottlieb, Alice B and Han, George and Khattri, Saakshi and Shaigany, Sheila and Weinberg, Jeffrey M and Lebwohl, Mark},
  title = {The efficacy and safety of IL-17 and IL-23 inhibitors in psoriatic arthritis across multiple disease domains},
  journal = {Dermatology Online Journal},
  year = {2026},
  volume = {32},
  number = {2},
  doi = {10.25251/zsav4a48}
}
Kostenlos starten →